Treatment of menopausal symptoms: what shall we do now?

• Published in: The Lancet (British edition) 2005-07, Vol.366 (9483), p.409-421
• Main Authors: Hickey, Martha, Davis, Susan R, Sturdee, David W
• Format: Article
• Language: English
• Subjects: Biological and medical sciences; Breast cancer; Breast Neoplasms - chemically induced; Comparative studies; Disease management; Estrogen Receptor Modulators - therapeutic use; Estrogen Replacement Therapy - adverse effects; Female; General aspects; Health risk assessment; Histology; Hormone replacement therapy; Humans; Medical sciences; Menopause; Menopause - drug effects; Norpregnenes - therapeutic use; Observational studies
• ISSN: 0140-6736; 1474-547X
• DOI: 10.1016/S0140-6736(05)66519-1

During the past few years, many women and doctors have revised their opinions of hormone replacement therapy (HRT) for menopausal symptoms, and a substantial number of individuals have discontinued its use because of concerns about side-effects. Numerous alternatives to HRT are promoted, and assessment of the quality of evidence about the safety and effectiveness of these compounds can be difficult. In this Review, we summarise the data from studies addressing the efficacy, risks, and benefits of frequently prescribed treatments, and offer evidence-based clinical guidelines for the management of menopausal symptoms. Although few comparative studies exist, oestrogen alone or combinations of oestrogen and progestagen are likely to be the most effective treatments for menopausal hot flushes and vaginal dryness. Tibolone is as effective as HRT, however, and might also improve libido. For those who wish to avoid hormonal treatments, there are few effective options. Selective serotonin reuptake inhibitors might be effective in the very short term (less than 12 weeks) and are well tolerated. There is not enough evidence that any of the complementary therapies available are any better than placebo for menopausal vasomotor symptoms, and few safety data exist.